EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is uniformly lethal. T-cell-based immunotherapy offers a promising platform for treatment given its potential to specifically target tumor tissue while sparing the normal brain. However, the diffuse and infiltrative na...
Main Authors: | Hongsheng Miao, Bryan D Choi, Carter M Suryadevara, Luis Sanchez-Perez, Shicheng Yang, Gabriel De Leon, Elias J Sayour, Roger McLendon, James E Herndon, Patrick Healy, Gary E Archer, Darell D Bigner, Laura A Johnson, John H Sampson |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3983153?pdf=render |
Similar Items
-
Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
by: Ayguen Sahin, et al.
Published: (2018-01-01) -
EGFRvIII: An Oncogene with Ambiguous Role
by: Adrianna Rutkowska, et al.
Published: (2019-01-01) -
Development of an EGFRvIII specific recombinant antibody
by: Li Gordon, et al.
Published: (2010-10-01) -
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
by: Vidyalakshmi Chandramohan, et al.
Published: (2019-05-01) -
Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited
by: Nicola Montano, et al.
Published: (2011-12-01)